Clinical Trials Logo

Age-Related Macular Degeneration clinical trials

View clinical trials related to Age-Related Macular Degeneration.

Filter by:

NCT ID: NCT05187104 Enrolling by invitation - Clinical trials for Age-Related Macular Degeneration

Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of age-related macular degeneration using retinal stem and progenitor cells

NCT ID: NCT05135195 Completed - Glaucoma Clinical Trials

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

Start date: October 24, 2021
Phase: N/A
Study type: Interventional

In this study, the study team utilize virtual reality (VR) to simulate visual impairments of different types and severity in healthy subjects. The platform implements three of the most widespread forms of visual impairment in the United States (US): age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, each with three levels of severity, (mild, moderate, and severe). At present, glaucoma is further developed toward a multidimensional visual impairment simulation. The platform is utilized: i) to provide a safe, controllable, and repeatable set of environments for development and preliminary testing of electronic travel aids (ETAs) in a variety of conditions (i.e., using the ETA to navigate in the immersed environment); and ii) to equip blind and low vision (BVI) professionals, inclusive of orientation and mobility (O&M) instructors, with a controlled, tunable training platform for skill/capacity building, assessment, and refinement of O&M techniques, as well as visually impaired trainees with a safe and immersive environment to improve their O&M skills and learn novel techniques. Two sets of hypothesis-driven experiments are proposed to assess the feasibility of the platform with respect to these two objectives.

NCT ID: NCT05112861 Active, not recruiting - Clinical trials for Diabetic Macular Edema

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NORSE SEVEN
Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.

NCT ID: NCT05091476 Recruiting - Clinical trials for Age-Related Macular Degeneration

OcuDyne System in the Treatment of AMD

Start date: July 25, 2022
Phase: N/A
Study type: Interventional

Feasibility of the OcuDyne OPTiC System in patients with late-stage non-exudative age-related macular degeneration.

NCT ID: NCT05064865 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Impact of Regular Consumption of Grapes on Eye Health in Singapore Older Adults

Start date: January 28, 2022
Phase: N/A
Study type: Interventional

Aging epidemics in Singapore are rapidly increasing and Age-related macular degeneration (AMD) prevalence is significantly associated with older age. This study aims to understand the effect of consuming freeze-dried table grape powder on AMD in an older population.

NCT ID: NCT05062486 Recruiting - Clinical trials for Age-related Macular Degeneration

A Study to Evaluate the Safety and Efficacy of RQC for AMD

Start date: July 22, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).

NCT ID: NCT05005884 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

In this multi-center study, possible effects of supplement treatment with oral phenolics on plasma CD-163 and progression of dry and wet age-related macular degeneration (AMD) via evaluating the CD163 before and after the prescription of this drug will be evaluated in patients with dry type AMD and Neo vascular age-related macular degeneration (nAMD). Both AMD subgroups will be recruited. In terms of evaluation of the effects of phenolics (500 mg caplets/day) on AMD progression, patients will be randomized and divided into 2 subgroups i.e. (i) receiving phenolics supplementation; and, (ii) receiving placebo for 1 month. The phenolics/placebo caplets will resemble completely and be encoded at origin; Neither the participants nor the researchers will be informed about the codes until the end of the study.

NCT ID: NCT05003245 Recruiting - Clinical trials for Age Related Macular Degeneration

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.

NCT ID: NCT04993352 Completed - Clinical trials for Age Related Macular Degeneration

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

Start date: July 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)

NCT ID: NCT04929756 Recruiting - Clinical trials for Age Related Macular Degeneration

Eye Movement Rehabilitation in Low Vision Patients

Start date: September 4, 2020
Phase:
Study type: Observational

Approximately 217 million people worldwide currently suffer from low vision, which impacts a broad range of activities of daily living and is associated with depression and increased mortality. Over half of the patients presenting for low vision services have eye disease that affects the fovea and surrounding macula and leads to central vision loss (CVL). People with CVL are forced to use eccentric vision as a substitute for their impaired fovea, however eye movement control and visual function is impaired with eccentric vision. Recent evidence and preliminary results from the investigators show that rehabilitation methods can help improve oculomotor control and this can lead to improved functional outcomes. The investigators have developed new feedback-based training methods that aim to improve eccentric vision use by patients with CVL. In a series of studies, the investigators examine rehabilitation of fixation control, smooth pursuit eye movements that track moving objects and saccadic eye movements that abruptly change the point of regard. The investigators examine how visual feedback, scotoma awareness methods and hand-eye coordination can improve eccentric vision use. Improvements in oculomotor control are quantified with eye tracking methods and associated changes in visual function are quantified with acuity, contrast sensitivity and reading performance. The proposed research therefore develops and translates state-of-the-art methods in basic science to clinical applications. Accomplishing the proposed aims will provide new and improved methods for rehabilitation strategies for visual impairment. The ultimate goal of this proposal is to maximize the residual visual function of people with low vision and to help them to live independently, thereby improving quality of life and minimizing the economic and social burden of visual impairment.